Views & Analysis | Perspectives on pharma industry issues

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Articles

Tunnah’s musings: pharma deals with the January pipeline blu...

As 2012 gets under way it looks like big pharma has an appetite for spending money, but is buying up all the biotechs really going to deliver the innovation the industry needs? Whilst most of us are tightening our belts after another festive season, it seems like big pharma is in the mood for even more shopping in January…

Articles

Physician perspectives: Mike Sevilla

Kicking off our new physician series, family physician Mike Sevilla who acts as a social media ambassador to the Family Medicine Physician community shares his thoughts on how beneficial social media is to him and how other physicians can become engaged. Mike Sevilla, a family physician, was formerly known as doctor anonymous and currently blogs at the site ‘Family medicine rocks’. Through his blogs...

Articles

Pharma vs. physician: how data can relieve the headache (par...

In part one of a two-part article Kabir Shahani teaches how the right data can be used to gain a better insight into your target audience and achieve a competitive advantage. As a founder of a healthcare software company, I hear leaders across the healthcare industry – from creative services companies to pharma executives…

Sales & Marketing

The independent pharmacy opportunity pharma marketers are ov...

Pharma marketers often underestimate the value of independent pharmacies.

Sales & Marketing

Sponsored

Accelerating growth through strategic investment in healthca...

CEVA FORPATIENTS at Rockingham, UK will offer the healthcare supply chain a new, sustainably designed multi-user site.

Digital

Sponsored

AI-enabled pharmacovigilance, with Updesh Dosanjh

Updesh Dosanjh, IQVIA commercialisation lead for safety technology, discusses how and why the role of AI in pharmacovigilance is changing.

Digital

Two female silhouettes in a city office overlook the urban landscape below

How female leadership can benefit industry

Day One Strategy’s founding partners Abigail Stuart and Hannah Mann share the benefits female leadership can bring to industry.

Market Access

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology